Ftse Mib
34.460,52
0,00%
DAX
18.680,20
-0,25%
S&P 500
5.307,01
-0,27%
NASDAQ
16.801,54
-0,18%
Bitcoin
69.417,51
0,46%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Canada TSX ProMIS Neurosciences Inc (PMN) ProMIS Neurosciences Inc (PMN) Notizie

PMN

ProMIS Neurosciences (PMN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:TSX:PMN
DataOraFonteTitoloSimboloCompagnia
18/04/202215:05PR Newswire (US)Argus Research Initiates Equity Report Coverage on ProMIS Neurosciences, Inc. (TSX:PMN & OTCQB: ARFXF)TSX:PMNProMIS Neurosciences Inc
18/08/202114:15PR Newswire (Canada)L'OCRCVM permet la reprise de la négociation - PMNTSX:PMNProMIS Neurosciences Inc
18/08/202114:13PR Newswire (Canada)IIROC Trade Resumption - PMNTSX:PMNProMIS Neurosciences Inc
17/08/202122:53PR Newswire (Canada)Suspension de la négociation par l'OCRCVM - PMNTSX:PMNProMIS Neurosciences Inc
17/08/202122:50PR Newswire (Canada)IIROC Trading Halt - PMNTSX:PMNProMIS Neurosciences Inc
18/11/201913:30PR Newswire (Canada)ProMIS Neurosciences Completes First Closing of Private PlacementTSX:PMNProMIS Neurosciences Inc
14/11/201913:30PR Newswire (Canada)ProMIS Neurosciences Announces Third Quarter 2019 ResultsTSX:PMNProMIS Neurosciences Inc
13/11/201913:30PR Newswire (Canada)ProMIS Neurosciences Undertaking $6.5M Private PlacementTSX:PMNProMIS Neurosciences Inc
07/11/201913:30PR Newswire (US)ProMIS Neurosciences outlines best-in-class approach to amyloid-beta-targeting drug candidates for Alzheimer's diseaseTSX:PMNProMIS Neurosciences Inc
24/10/201909:00PR Newswire (US)ProMIS Neurosciences issues Chairman's update memorandum and white paper on Alzheimer's diseaseTSX:PMNProMIS Neurosciences Inc
23/10/201915:49PR Newswire (US)ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43TSX:PMNProMIS Neurosciences Inc
17/10/201913:30PR Newswire (US)ProMIS Neurosciences advances Alzheimer's disease program targeting neurotoxic forms of tauTSX:PMNProMIS Neurosciences Inc
08/10/201913:30PR Newswire (US)ProMIS Neurosciences Identifies Novel Antibody Candidates for Multiple System AtrophyTSX:PMNProMIS Neurosciences Inc
03/09/201913:30PR Newswire (US)ProMIS Neurosciences to Present at HC Wainwright Investment ConferenceTSX:PMNProMIS Neurosciences Inc
27/08/201913:30PR Newswire (Canada)ProMIS Neurosciences Appoints Internationally Recognized Researcher in Alzheimer's Disease in Down Syndrome Dr. Andre Strydom...TSX:PMNProMIS Neurosciences Inc
13/08/201913:30PR Newswire (Canada)ProMIS Neurosciences Announces Second Quarter 2019 ResultsTSX:PMNProMIS Neurosciences Inc
24/07/201913:30PR Newswire (Canada)ProMIS Neurosciences Announces Results of Annual Meeting of ShareholdersTSX:PMNProMIS Neurosciences Inc
18/07/201921:00PR Newswire (US)ProMIS Neurosciences Highlights Data for PMN310 at AAIC 2019TSX:PMNProMIS Neurosciences Inc
10/07/201913:30PR Newswire (Canada)ProMIS Neurosciences to Present Data at 2019 Alzheimer's Association International ConferenceTSX:PMNProMIS Neurosciences Inc
09/07/201913:30PR Newswire (US)ProMIS Neurosciences' Data for Alzheimer's Disease Clinical Candidate PMN310 Published in Scientific ReportsTSX:PMNProMIS Neurosciences Inc
27/06/201913:30PR Newswire (Canada)ProMIS Neurosciences' PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed AntibodiesTSX:PMNProMIS Neurosciences Inc
26/06/201913:30PR Newswire (Canada)ProMIS Neurosciences Closing Private PlacementTSX:PMNProMIS Neurosciences Inc
19/06/201913:30PR Newswire (US)ProMIS Neurosciences Appoints Renowned Parkinson's Disease Expert Dr. C. Warren Olanow to Scientific Advisory BoardTSX:PMNProMIS Neurosciences Inc
05/06/201913:30PR Newswire (US)ProMIS Neurosciences Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific ConferenceTSX:PMNProMIS Neurosciences Inc
29/05/201913:30PR Newswire (US)ProMIS Neurosciences' Eugene Williams to Present at JLABS' Conference on Innovations in Neurodegenerative DiseasesTSX:PMNProMIS Neurosciences Inc
28/05/201913:30PR Newswire (US)ProMIS Neurosciences Identifies Novel Antibodies for Alzheimer's Disease with Selectivity for the Neurotoxic Form of TauTSX:PMNProMIS Neurosciences Inc
14/05/201913:30PR Newswire (US)ProMIS Neurosciences Announces First Quarter 2019 ResultsTSX:PMNProMIS Neurosciences Inc
23/04/201913:30PR Newswire (US)ProMIS Neurosciences to Participate in the Think Equity Investor ConferenceTSX:PMNProMIS Neurosciences Inc
26/03/201912:30PR Newswire (US)ProMIS Neurosciences to Participate in Microcap Spring Investor Summit 2019TSX:PMNProMIS Neurosciences Inc
21/03/201919:47PR Newswire (US)Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer's DiseaseTSX:PMNProMIS Neurosciences Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:TSX:PMN

La tua Cronologia

ASX
ACE
Acusensus
TG
AB1B
Air Berlin
BIT
P1V4Q4
NLBNPIT1V4Q4 20351221 95...
BIT
P1TFA0
NLBNPIT1TFA0 20240621 13
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network